-
1Academic Journal
Συγγραφείς: Korneva, K. G., Strongin, L. G., Pimankina, M. S., Grunina, E. A., Sazanova, N. M., Shlyakova, A. A., Корнева, К. Г., Стронгин, Л. Г., Пиманкина, М. С., Грунина, Е. А., Сазанова, Н. М., Шлякова, А. А.
Θεματικοί όροι: TYPE 2 DIABETES MELLITUS, CHRONIC VENOUS DISEASE, SKIN MICROCIRCULATION, JOINT SYNDROME, САХАРНЫЙ ДИАБЕТ 2 ТИПА, ХРОНИЧЕСКАЯ ВЕНОЗНАЯ БОЛЕЗНЬ, КОЖНАЯ МИКРОЦИРКУЛЯЦИЯ, СУСТАВНОЙ СИНДРОМ
Περιγραφή αρχείου: application/pdf
Relation: Уральский медицинский журнал. 2020. № 8(191).; http://elib.usma.ru/handle/usma/19134
Διαθεσιμότητα: http://elib.usma.ru/handle/usma/19134
-
2Academic Journal
Συγγραφείς: M. A. Vinogradova, T. V. Kirsanova, D. S. Serebriyskaya, М. А. Виноградова, Т. В. Кирсанова, Д. С. Серебрийская
Πηγή: Meditsinskiy sovet = Medical Council; № 3 (2020); 68-73 ; Медицинский Совет; № 3 (2020); 68-73 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2020-3
Θεματικοί όροι: прегравидарная подготовка, sulodexide, reproductive losses, chronic venous disease, pregravid preparation, сулодексид, репродуктивные потери, хроническая венозная болезнь
Περιγραφή αρχείου: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/5572/5076; Черняховская Н.Е., Шишло В.К., Поваляев А.В. Коррекция микроциркуляции в клинической практике. М.: Бином; 2013. 208 с.; Cicinelli E., De Ziegler D., Nicoletti R., Colafiglio G., Saliani N., Resta L. et al. Chronic endometritis: correlation among hysteroscopic, histologic, and bacteriologic findings in a prospective trial with 2190 consecutive office hysteroscopies. Fertil Steril. 2008;89(3):677–684. doi:10.1016/j.fertnstert.2007.03.074.; Kimura F., Takebayashi A., Ishida M., Nakamura A., Kitazawa J., Morimune A. et al. Review: Chronic endometritis and its effect on reproduction. J Obstet Gynaecol Res. 2019;45(5):951–960. doi:10.1111/jog.13937.; Hoppensteadt D.A., Fareed J. Pharmacological profile of sulodexide. Int Angiol. 2014;33(3):229–235. Available at: https://www.ncbi.nlm.nih.gov/pubmed/24936531.; Masola V., Zaza G., Onisto M., Lupo A., Gambaro G. Glycosaminoglycans, proteoglycans and sulodexide and the endothelium: biological roles and pharmacological effects. Int Angiol. 2014;33:243–254. Available at: https://www.ncbi.nlm.nih.gov/pubmed/24936533.; Zhang X., Sun D., Song J.W., Zullo J., Lipphardt M., Coneh-Gould L., Goligorsky M.S. Endothelial cell dysfunction and glycocalyx – A viscious circle. Matrix Biol. 2018;71–72:421–431. doi:10.1016/j.matbio.2018.01.026.; Veraldi N., Guerrini M., Urso E., Risi G., Bertini S., Bensi D., Bisio A. Fine structural characterization of sulodexide. J Pharm Biomed Anal. 2018;156:67–79. doi:10.1016/j.jpba.2018.04.012.; Coccheri S., Mannello F. Development and use of sulodexide in vascular diseases: implications for treatment. Drug Des Devel Ther. 2013;8:49–65. doi:10.2147/DDDT.S6762.; Harenberg J. Review of pharmacodynamics, pharmacokinetics and therapeutic properties of sulodexide. Med Res. 1998;18(1):1–20. doi:10.1002/(SICI)1098-1128(199801)18:13.0.CO;2-4.; Milani M.R., Busutti L., Breccia A. Pharmacokinetics of sulodexide evaluation from 131-labelled fast-moving heparin after single intravenous and oral administration on man at different doses. Brit J Clin Res. 1992;3:161–178.; Carroll B.J., Piazza G., Goldhaber S.Z. Sulodexide in Venous Disease. J Thromb Haemost. 2019;17(1):31–38. doi:10.1111/jth.14324.; Cosmi B., Cini M., Legnani C., Pancani C., Calanni F., Coccheri S. Additive thrombin inhibition by fast moving heparin and dermatan sulfate explains the anticoagulant effect of sulodexide, a natural mixture of glycosaminoglycans. Thromb Res. 2003;109(5–6):333–339. doi:10.1016/S00493848(03)00246-9.; Mauro M., Ferraro G., Palmieri G.C. Profibrinolytic and antithrombotic effects of sulodexide oral administration: a double-blind, cross-over, placebocontrolled study. Curr Ther Res. 1992;51:342–350.; Cerletti C., Rajtar G., Marchi E., De Gaetano G. Interaction between glycosaminoglycans, platelets, and leukocytes. Semin Thromb Hemost. 1994;20(3):245–253. doi:10.1055/s-2007-1001909.; Young E. The anti-inflammatory effects of heparin and related compounds. Thromb Res. 2008;122(6):743–752. doi:10.1016/j.thromres.2006.10.026.; Ligi D., Croce L., Mosti G., Raffetto J.D., Mannello F. Chronic venous insufficiency: Transforming growth factor-beta isoforms and soluble endoglin concentration in different states of wound healing. Int J Mol Sci. 2017;18(10):2206. doi:10.3390/ijms18102206.; Mannello F., Ligi D., Raffetto J.D. Glycosaminoglycan sulodexide modulates inflammatory pathways in chronic venous disease. Int Angiol. 2014;33(3):236–242. Availale at: https://www.ncbi.nlm.nih.gov/pubmed/24936532.; Mannello F., Ligi D., Canale M., Raffetto J.D. Sulodexide down-regulates the release of cytokines, chemokines, and leukocyte colony stimulating factors from human macrophages: role of glycosaminoglycans in inflammatory pathways of chronic venous disease. Curr Vasc Pharmacol. 2014;12(1):173–185. doi:10.2174/1570161111666131126144025.; Ciszewicz M., Polubinska A., Antoniewicz A., Suminska-Jasinska K., Breborowicz A. Sulodexide suppresses inflammation in human endothelial cells and prevents glucose cytotoxicity. Transl Res. 2009;153(3):118–123. doi:10.1016/j.trsl.2008.12.007.; Blich M., Golan A., Arvatz G., Sebbag A., Shafat I., Sabo E. et al. Macrophage activation by heparanase is mediated by TLR-2 and TLR-4 and associates with plaque progression. Arterioscler Thromb Vasc Biol. 2013;33(2):e56– e65. doi:10.1161/ATVBAHA.112.254961.; Andreozzi G.M. Role of sulodexide in the treatment of CVD. Int Angiol. 2014;33(3):255–262.; Mannello F., Medda V., Ligi D., Raffetto J.D. Glycosaminoglycan sulodexide inhibition of MMP-9 gelatinase secretion and activity: possible pharmacological role against collagen degradation in vascular chronic diseases. Curr Vasc Pharmacol. 2013;11(3):354–365. doi:10.2174/1570161111311030010.; Ligi D., Mosti G., Croce L., Raffetto J.D., Mannello F. Chronic venous disease – part II: Proteolytic biomarkers in wound healing. Biochim Biophys Acta (BBA). 2016;1862(10):1900–1908. doi:10.1016/j.bbadis.2016.07.011.; Meissner M.H., Eklof B., Smith P.C., Dalsing M.C., DePalma R.G., Gloviczki P. et al. Secondary chronic venous disorders. J Vasc Surg. 2007;46(6):S68S– S83. doi:10.1016/j.jvs.2007.08.048.; Chatterjee S. Endothelial mechanotransduction, redox signaling and the regulation of vascular inflammatory pathways. Front Physiol. 2018;9:1–16. doi:10.3389/fphys.2018.00524.; Bergan J.J., Schmid-Schönbein G.W., Coleridge Smith P.D., Nicolaides A.N., Boisseau M.R., Eklof B. Chronic venous disease. N Engl J Med. 2006;355:488–498. doi:10.1056/NEJMra055289.; Elleuch N., Zidi H., Bellamine Z., Hamdane A., Guerchi M., Jellazi N. Sulodexide in patients with chronic venous disease of the lower limbs: clinical efficacy and impact on quality of life. Adv Ther. 2016;33:1536– 1549. doi:10.1007/s12325-016-0359-9.; Raffetto J.D. Dermal pathology, cellular biology, and inflammation in chronic venous disease. Thromb Res. 2009;123:S66–S71. doi:10.1016/S0049-3848(09)70147-1.; Mansilha A., Sousa J. Pathophysiological mechanisms of chronic venous disease and implications for venoactive drug therapy. Int J Mol Sci. 2018;19(6):1–21. doi:10.3390/ijms19061669.; Kearon C., Kahn S.R., Agnelli G., Goldhaber S., Raskob G.E., Comerota A.J. Antithrombotic therapy for venous thromboembolic disease: American College of Chest physicians evidence-based clinical practice guidelines (8th ed.). Chest. 2008;133(6):454S–545S. doi:10.1378/chest.08-0658.; Engberink O., Rorije N.M., Lambers Heersprink H.J., Zeeuw D.D., Born van den B.-J.H., Vogt L. The blood pressure lowering potential of sulodexide – a systematic review and meta-analysis. Br J Clin Pharmacol. 2015;80(6):1245–1253. doi:10.1111/bcp.12722.; Кузнецова И.В. Роль преконцепционной эндотелиальной дисфункции в развитии акушерских осложнений. Медицинский алфавит. 2019;1(1):53–58. doi:10.33667/2078-5631-2019-1-1(376)-53-58.
-
3Academic Journal